[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-661309-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-661309-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","retooling-your-immune-system-in-vivo-to-fight-cancer-multi-functional-cell-therapies-summit-may-2021","Retooling Your Immune System In Vivo to Fight Cancer - Multi-Functional Cell Therapies Summit - May 2021","","A confidential presentation outlining Umoja’s in vivo immunotherapy platform aimed at improving access to immunotherapy by retooling a patient’s immune system. The talk describes integrated solutions for CAR-T challenges in blood and solid tumors, including fixed CAR specificity and universal TagCAR approaches. It details VivoVec for in vivo CAR T generation via lymph node delivery and subsequent tumor trafficking, and RACR for in vivo CAR T expansion controlled by a Rapamycin Activated Cytokine Receptor system. It also presents TumorTag combinatorial targeting using SMOL adapters and swappable tumor/stroma labels.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/retooling-your-immune-system-in-vivo-to-fight-cancer-multi-functional-cell-therapies-summit-may-2021/661309/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/retooling-your-immune-system-in-vivo-to-fight-cancer-multi-functional-cell-therapies-summit-may-2021/661309.png","ImageObject",300,407,{"name":42,"@type":43},"Blue Pony","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-10-28",true,{"@type":52,"interactionType":53,"userInteractionCount":22},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"What is Umoja’s primary mission in this presentation?","Question",{"text":62,"@type":63},"To advance and improve access to immunotherapy by retooling the patient’s immune system in vivo, reducing the burden of cancer in daily life.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"How does VivoVec generate CAR T cells in vivo?",{"text":67,"@type":63},"VivoVec particles are delivered to lymph nodes, then bind, activate, and transduce T cells. The transduced T cells exit lymph nodes and traffic to the tumor.",{"name":69,"@type":60,"acceptedAnswer":70},"What role does RACR play in CAR T expansion?",{"text":71,"@type":63},"RACR provides control over in vivo CAR T expansion using a rapamycin-activated cytokine receptor system, enabling robust proliferation and survival while regulating undesired cell activity.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},661309,1793162869,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},7,40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":106,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":22,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":110,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":79,"read_time":117},962090760266,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Your Body.  \nYour Hope .  \nYour Cure .  \nRetooling Your Immune System In Vivo to Fight Cancer  \nMulit-Functional Cell Therapies Summit, May 2021  \nOur mission is to advance and improve access to immunotherapy by retooling the patient’s immune system in vivo, freeing them from the burden of cancer in their daily lives  \nCONFIDENTIAL 2  \nUmoja’s integrated immunotherapy platform provides solutions to the challenges in both blood and solid tumor CAR-T therapies  \nFixed CAR specificity  \nUniversal TagCAR  \n3  \nVivoVec : In vivo CAR T cell generation  \nFoundational concept:  \nlymph nodes are nature’s optimized T cell “manufactory”  \nUmoja leverages a deep understanding of the human immune system’s physiology  \nfor its proprietary approach to in vivo T cell engineering  \nVivoVec particles are delivered to lymph nodes  \nVivoVec particles bind, activate, and transduce Tcells  \nTransduced Tcells exit lymph nodes and traffic to tumor  \nCONFIDENTIAL  \n4  \nRACR: In vivo CAR T cell expansion  \nRACR: Rapamycin Activated Cytokine Receptor provides  \ncontrol over expansion  \n3-component RACR system  \n• Rapamycin activates the RACR system which replicates common g chain cytokine activating STAT5 signaling for robust proliferation and survival  \n• Naked intracellular FRB domain provides rapamycin resistance to transduced cells while non  \ntransduced T and B cells are repressed through mTOR inhibition  \nCONFIDENTIAL 5  \nTumorTag : Comb inatorial Tumor Targeting  \nTumorTag platform:  \nSMOL adapters for targeting of tumor and stroma  \nTAG Tumor ligand  \nuniversal fluorescein (FL)”Tag” antigen  \nSwappable ligands  \nAntigen-independent  \n  universal tumor label  \nTumorTag SMOL adapter suite  \nUB-TT170 (FL-folate)  \n\n| | TagCAR T-cells\u003Cbr>target tumor or stroma via“Tag” adapter bound to surface antigen | |\n| --- | --- | --- |\n\nCONFIDENTIAL  \n6  \nUmoja’s immunotherapy platform is designed to effectively and safely  \nretool the patient’s immune system against cancer  \nCONFIDENTIAL  \n7  \nThank you  \nUMOJA-BIOPHARMA. COM","cbCairC2aUneZ6cv","https://ap.wps.com/l/cbCairC2aUneZ6cv","pdf",5838821,"English","# Our Mission\n## Umoja’s Integrated Immunotherapy Platform\n## VivoVec: In vivo CAR T Cell Generation\n## RACR: In vivo CAR T Cell Expansion\n## TumorTag: Combinatorial Tumor Targeting\n# Platform Goal","[{\"question\":\"What is Umoja’s primary mission in this presentation?\",\"answer\":\"To advance and improve access to immunotherapy by retooling the patient’s immune system in vivo, reducing the burden of cancer in daily life.\"},{\"question\":\"How does VivoVec generate CAR T cells in vivo?\",\"answer\":\"VivoVec particles are delivered to lymph nodes, then bind, activate, and transduce T cells. The transduced T cells exit lymph nodes and traffic to the tumor.\"},{\"question\":\"What role does RACR play in CAR T expansion?\",\"answer\":\"RACR provides control over in vivo CAR T expansion using a rapamycin-activated cytokine receptor system, enabling robust proliferation and survival while regulating undesired cell activity.\"}]","Retooling Your Immune System In Vivo to Fight Cancer - Multi-Functional Cell Therapies Summit - May 2021 | PDF"]